ClinicalTrials.gg
RecruitingNCT06645691POLARIC-13Updated Nov 17, 2026

Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body

A Phase 2 interventional study of Hyperpolarized 13C-pyruvate in Heart Failure, Cardiometabolic Syndrome and Cancer Diagnosis, sponsored by National Heart Centre Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Heart Centre Singapore · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
21 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Heart Failure with a site in Singapore — 6 open to participants now, 14 under way, 2 of them phase 3. Heart Failure · Singapore.

Planned enrollment
30th of 46
200 · median 310
Started
2024
with 4 others
Phase 2
7 of 62
1 open now
Primary completion
2028-05
later than 9 of 13 live
Registered
58th of 62
by date
Lead sponsor
7 of 62
National Heart Centre Singapore

Among the 62 studies in Heart Failure with a site in Singapore, this one is the 30th largest by planned enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2024, is one of 7 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 58th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 62 studies in Heart Failure with a site in Singapore are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 21 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Heart Failure with a site in Singapore, or all of them as a file.
02

Study summary

Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.

Read the detailed description

Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan.

Carbon 13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. However, the low natural abundance of the 13C isotope at \~1.1% has made in vivo imaging extremely challenging. To improve the MR signal 13C nuclei, probes are synthetically enriched to increase the concentration of the 13C label in a molecule. MRI signal can be further increased by the process of hyperpolarization. At low temperature and high magnetic field, electrons have a very high level of polarization (ie, nearly all the electrons are aligned in the same direction). This high level of polarization can be transferred to 13C-labeled probes, increasing their MRI signals. This transfer of polarization is accomplished by mixing radicals (a source of free electrons) with the 13C-labeled probe(s) to be hyperpolarized and placing the mixture in a polarizer at a magnetic field typically of 3.0-5.0 T and at a low temperature (approximately 1 K). Microwave irradiation is then applied to transfer the polarization from unpaired electrons in a trityl radical to the 13C-labeled probe. The final solution retains a high level of polarization and can be formulated to be at physiologic pH, osmolarity, and temperature for in vivo injection and metabolic investigations.

With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal (Figure 1). The enhanced signal, however, is typically available only for a short period of time (1-2 minutes), as the polarization decays back to its thermal equilibrium level. Therefore, rapid imaging is needed to acquire high signal-to-noise ratio metabolic data with minimal polarization loss and to measure fast metabolic processes.

To date, hyperpolarized imaging technique has been performed in more than 800 healthy volunteers and patients; and in more than 1,200 studies in various clinical conditions.

HYPOTHESIS AND OBJECTIVES:

This proof-of-concept study to demonstrate feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular/cardiometabolic diseases.

  1. To establish reference ranges in the metabolic products of hyperpolarized 13C-pyruvate (lactate, alanine and bicarbonate) in healthy volunteers and examine repeatability of the 13C hyperpolarized imaging sequences.
  2. To develop the application of 13C hyperpolarized imaging in patients with cardiovascular and cardiometabolic diseases.
03

Conditions studied

  • Heart Failure
  • Cardiometabolic Syndrome
  • Cancer Diagnosis
  • Cardiovascular Diseases
  • Healthy Volunteers

Keywords

  • Carbon-13 Pyruvate
  • Magnetic Resonance Imaging
  • Lactate
  • Alanine
  • Bicarbonate
  • Hyperpolarized Pyruvate (13C) Injection
04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Volunteers:

  1. Age 21 years and above
  2. No significant medical co-morbidities (such as chronic kidney disease, diabetes mellitus, heart failure, ischemic heart disease, previous strokes)
  3. No history of cancer
  4. Able and willing to comply with study procedures and provide signed

Patients with cardiovascular/cardiometabolic diseases:

  1. Age 21 years and above
  2. Physician diagnosed cardiovascular conditions: ischemic heart disease, inherited cardiomyopathies (hypertrophic, dilated or infiltrative cardiomyopathies) and stable heart failure; and/or
  3. Cardiometabolic conditions (such as diabetes on medications, hypertension, central obesity, fatty liver disease)
  4. Able and willing to comply with study procedures and provide signed informed consent

Exclusion criteria

Exclusion Criteria:

  1. Standard for magnetic resonance procedures (such as implantable medical devices, suspected presence of surgical apparatus or shrapnel, severe claustrophobia)
  2. Unstable medical conditions (such as symptomatic heart failure, unstable hypertension/glucose levels as determined by investigators, symptomatic arrhythmias, angina)
  3. Pregnant or nursing women
  4. Known allergies to pyruvate or any of its components
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Hyperpolarized Pyruvate [13C] Injection

    Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner.

    Drug: Hyperpolarized 13C-pyruvate

Interventions

06

What researchers measure

Primary outcomes

  1. Feasibility and reproducibility of Imaging Technique

    Feasibility and reproducibility of the imaging technique in healthy volunteers and patients with cardiovascular and/or cardiometabolic diseases

    Time frame: 30 - 45 minutes post dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for May 2028, 43 months after the start.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 43 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 17, 2024
StartActual
Oct 17, 2024
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and oversight details
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06645691
Lead sponsor
National Heart Centre Singapore
Collaborators
National Medical Research Council (NMRC), Singapore
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Oct 17, 2024
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Calvin WL Chin
Contact
CAMI@nhcs.com.sg
6568449055

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyperpolarized Carbon C 13 (1-13C) Pyruvate

Start the discussion